Resultado final Documents, reports (34) 4.3 Generate VLPs for two TBV candidates and assess immunogenicity/TB Generate VLPs for two TBV candidates and assess immunogenicity and TB activity 6.4 Preclinical studies completed for adjuvant Preclinical studies completed for adjuvant 7.5 Report on safety and immunogenicity of vectored prime-target immunisation in healthy volunteers Report on safety and immunogenicity of vectored prime-target immunisation in healthy volunteers 1.5 Generation of 8 transgenic P berghei parasites expressing novel P falciparum antigens Creation of 8 transgenic P. berghei parasites expressing novel P. falciparum sporozoite antigens 10.2 Establish relevant committees including PSC, PMMC, ISAC Report on the establishment of relevant committees including the Project Steering Committee and a Project Management and Monitoring Committee, and ISAC 2.1 Liver-stage antigens identified from HLA molecules of parasitized hepatocytes Report on the nature of liver-stage antigens identified by sequencing of eluted peptides from the HLA molecules of parasitized hepatocytes 5.2 Adequate process for lead novel VLPs for initial GMP production Adequate process for lead novel VLPs for initial (Phase I trial scale) GMP production 2.3 Rank ordering of the protective efficacy of new liver-stage antigen candidates Rank ordering of the protective efficacy of new liverstage antigen candidates assessed in in vivo murine models using transgenic parasite challenge 5.1 generation of five new VLPs with SnoopCatcher and SpyCatcher Report on generation of five new VLPs with SnoopCatcher and SpyCatcher and on the relative robustness of each platform for displaying multiple antigens 1.4 Generation of 8 new vectored vaccine candidates Generation of 8 new vectored vaccine candidates expressing the 8 elected antigens of deliverable 1.1. 1.3 Generation of lead bivalent sporozoite VLP suitable for progression to GMP Generation of lead bivalent sporozoite VLP suitable for progression to GMP biomanufacture 4.1 Identification of new novel candidates from natural blockers and proteomic screen Identification of new novel candidates from natural blockers and proteomic screen 4.5 Assess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufacture Assess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufacture 3.4 Efficacy of new candidate blood-stage antigens Report on efficacy of new candidate bloodstage antigens 3.1 Preferred VLP for generation of bi-valent blood-stage immunogen Report on preferred VLP for generation of a bi-valent blood-stage immunogen 3.2 Immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLP Report on the immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLP 5.3 Comparison of immunogenicity of lead VLPs and evidence of non-interference Comparison of immunogenicity of the VLPs generated with identification of the lead VLPs and evidence of non-interference between lead sporozoite-, blood-stage and transmission-stage VLPs 7.7 Report on safety and immunogenicity of R21b in matrix M adjuvant Report on safety and immunogenicity of R21b in matrix M adjuvant 2.4 Utility of new prime-target immunisation approaches in liver-stage protective immunity in mice Report of the utility of new primetarget immunisation approaches in generating durable liverstage protective immunity in mice 1.6 Efficacy data on new antigens allowing rank ordering Efficacy data on new sporozoite antigens allowing rank ordering of protective efficacy of lead antigens 8.4 Report on safety and immunogenicity of blood-stage VLP/vaccine Report on safety and immunogenicity of bloodstage VLPvaccine in clinical trial 10.8 List of publications List of publications arising from project including any at manuscript preparation stage as some data may not be published until after the end date of the project 4.2 Validation of selected novel candidate and comparison with leading antigens Validation of selected novel candidate and comparison with leading antigens 7.6 Report on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteers Report on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteers 3.3 Structural studies of PfRH5 pathway components Report on structural studies of PfRH5 pathway components 9.5 TB activity of TBV candidates Transmission Blocking activity of TBV candidates 5.4 Optimised process for biomanufacture of lead novel VLPs for GMP production Optimised process for biomanufacture of lead novel VLPs for high yield larger scale GMP production 2.2 Ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopes Report on the ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopes inserted into P. falciparum liver-stage antigens by CRISPR/Cas9 technology 4.4 Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs 8.5 Report on immuno-efficacy of blood-stage VLP/vaccine Report on immunoefficacy of bloodstage VLPvaccine in clinical trial 1.2 Definition of 8 selected new candidate sporozoite antigens Definition of 8 selected new candidate sporozoite antigens based on invasion analysis, proteomics and immunoepidemiology 9.4 Safety and Immunogenicity of TBV candidates Safety and Immunogenicity of TBV candidates 7.8 Report on efficacy against sporozoite challenge of vectored prime-target immunisation combined with R21b in healthy volunteers Report on efficacy against sporozoite challenge of vectored primetarget immunisation combined with R21b in healthy volunteers 5.5 feasibility of enhancing the durability of protective immune responses using VLPs in microcapsules Report on the feasibility of enhancing the durability of protective immune responses using VLPs in microcapsules Websites, patent fillings, videos etc. (1) 10.1 Creation of website Successful creation of project website Publicaciones Peer reviewed articles (15) Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates Autores: Roos M. de Jong, Susheel K. Singh, Karina Teelen, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Will J. R. Stone, Emily Locke, Jordan Plieskatt, Michael Theisen, Teun Bousema, Matthijs M. Jore Publicado en: Frontiers in Immunology, 2022, ISSN 1664-3224 Editor: Frontiers Media SA DOI: 10.3389/fimmu.2022.909060 Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites Autores: Surendra Kumar Kolli, Ahmed M. Salman, Jai Ramesar, Severine Chevalley-Maurel, Hans Kroeze, Fiona G. A. Geurten, Shinya Miyazaki, Ekta Mukhopadhyay, Catherin Marin-Mogollon, Blandine Franke-Fayard, Adrian V. S. Hill, Chris J. Janse Publicado en: PLOS ONE, Issue 16/7, 2021, Page(s) e0254498, ISSN 1932-6203 Editor: Public Library of Science DOI: 10.1371/journal.pone.0254498 Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine Autores: Susheel K. Singh1,2, Jordan Plieskatt3, Bishwanath K. Chourasia1,2, Vandana Singh1,2, Karin Lövgren Bengtsson4, Jenny M. Reimer 4, Renate C. van Daalen5, Karina Teelen5, Marga van de Vegte-Bolmer5, Geert-Jan van Gemert5, Matthijs M. Jore 5,6✉ and Michael Theisen Publicado en: NPJ Vaccines, 2021, ISSN 2059-0105 Editor: Springer Nature DOI: 10.1038/s41541-021-00383-8 Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies Autores: Ko KT, Lennartz F, Mekhaiel D, Guloglu B, Marini A, Deuker DJ, Long CA, Jore MM, Miura K, Biswas S, Higgins MK Publicado en: Nature Communications, 2022, ISSN 2041-1723 Editor: Nature Publishing Group DOI: 10.1038/s41467-022-33379-6 A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine Autores: Susheel K. Singh, Jordan Plieskatt, Bishwanath K. Chourasia, Amanda Fabra-García, Asier Garcia-Senosiain, Vandana Singh, Karin Lövgren Bengtsson, Jenny M. Reimer, Robert Sauerwein, Matthijs M. Jore, Michael Theisen Publicado en: Frontiers in Immunology, Issue 11, 2021, ISSN 1664-3224 Editor: Frontiers in Immunology DOI: 10.3389/fimmu.2020.606266 Novel insights from the Plasmodium falciparum sporozoite-specific proteome by probabilistic integration of 26 studies. Autores: Meerstein-Kessel L, Venhuizen J, Garza D, Proellochs NI, Vos EJ, Obiero JM, et al. Publicado en: PLoS Comput. Biol., 2021, ISSN 1553-7358 Editor: PLOS DOI: 10.1371/journal.pcbi.1008067 Alpha-v–containing integrins are host receptors for the Plasmodium falciparum sporozoite surface protein, TRAP Autores: Kirsten Dundas, Melanie J. Shears, Yi Sun, Christine S. Hopp, Cecile Crosnier, Tom Metcalf, Gareth Girling, Photini Sinnis, Oliver Billker, Gavin J. Wright Publicado en: Proceedings of the National Academy of Sciences, Issue 115/17, 2018, Page(s) 4477-4482, ISSN 0027-8424 Editor: National Academy of Sciences DOI: 10.1073/pnas.1719660115 Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies Autores: Daniel G.W. Alanine, Doris Quinkert, Rasika Kumarasingha, Shahid Mehmood, Francesca R. Donnellan, Nana K. Minkah, Bernadeta Dadonaite, Ababacar Diouf, Francis Galaway, Sarah E. Silk, Abhishek Jamwal, Jennifer M. Marshall, Kazutoyo Miura, Lander Foquet, Sean C. Elias, Geneviève M. Labbé, Alexander D. Douglas, Jing Jin, Ruth O. Payne, Joseph J. Illingworth, David J. Pattinson, David Pulido, Barnab Publicado en: Cell, Issue 178/1, 2019, Page(s) 216-228.e21, ISSN 0092-8674 Editor: Cell Press DOI: 10.1016/j.cell.2019.05.025 A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response Autores: Arianna Marini, Yu Zhou, Yuanyuan Li, Iona J. Taylor, Darren B. Leneghan, Jing Jin, Marija Zaric, David Mekhaiel, Carole A. Long, Kazutoyo Miura, Sumi Biswas Publicado en: Frontiers in Immunology, Issue 10, 2019, Page(s) Artiicle 2931, ISSN 1664-3224 Editor: Unknown DOI: 10.3389/fimmu.2019.02931 Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum Autores: Susheel K. Singh, Susan Thrane, Bishwanath K. Chourasia, Karina Teelen, Wouter Graumans, Rianne Stoter, Geert-Jan van Gemert, Marga G. van de Vegte-Bolmer, Morten A. Nielsen, Ali Salanti, Adam F. Sander, Robert W. Sauerwein, Matthijs M. Jore, Michael Theisen Publicado en: Frontiers in Immunology, Issue 10, 2019, Page(s) Article 1256, ISSN 1664-3224 Editor: Unknown DOI: 10.3389/fimmu.2019.01256 Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens Autores: Paulo Bettencourt Publicado en: Frontiers in Immunology, Issue 11, 2020, Page(s) Article 190, ISSN 1664-3224 Editor: Unknown DOI: 10.3389/fimmu.2020.00190 Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites Autores: Roos M. Jong, Surafel K. Tebeje, Lisette Meerstein‐Kessel, Fitsum G. Tadesse, Matthijs M. Jore, Will Stone, Teun Bousema Publicado en: Immunological Reviews, Issue 293/1, 2019, Page(s) 190-215, ISSN 0105-2896 Editor: Blackwell Publishing Inc. DOI: 10.1111/imr.12828 Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens Autores: Joseph J. Illingworth, Daniel G. Alanine, Rebecca Brown, Jennifer M. Marshall, Helen E. Bartlett, Sarah E. Silk, Geneviève M. Labbé, Doris Quinkert, Jee Sun Cho, Jason P. Wendler, David J. Pattinson, Lea Barfod, Alexander D. Douglas, Michael W. Shea, Katherine E. Wright, Simone C. de Cassan, Matthew K. Higgins, Simon J. Draper Publicado en: Frontiers in Immunology, Issue 10, 2019, Page(s) Article 1254, ISSN 1664-3224 Editor: Unknown DOI: 10.3389/fimmu.2019.01254 Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters Autores: Shinya Miyazaki, Annie S. P. Yang, Fiona J. A. Geurten, Catherin Marin-Mogollon, Yukiko Miyazaki, Takashi Imai, Surendra Kumar Kolli, Jai Ramesar, Severine Chevalley-Maurel, Ahmed M. Salman, Geert-Jan A. van Gemert, Youri M. van Waardenburg, Blandine Franke-Fayard, Adrian V. S. Hill, Robert W. Sauerwein, Chris J. Janse, Shahid M. Khan Publicado en: Frontiers in Cellular and Infection Microbiology, Issue 10, 2020, ISSN 2235-2988 Editor: Frontiers Media S. A. DOI: 10.3389/fcimb.2020.00270 CRISPR/Cas9-engineered inducible gametocyte producer lines as a valuable tool for Plasmodium falciparum malaria transmission research Autores: Boltryk SD, Passecker A, Alder A, Carrington E, van de Vegte-Bolmer M, van Gemert G-J, et al Publicado en: Nature Communications, 2021, ISSN 2041-1723 Editor: Nature Publishing Group DOI: 10.1038/s41467-021-24954-4 Other (1) A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host-pathogen interactions Autores: Rameswara Reddy Segireddy, Kirsten Dundas, Julia Knoeckel, Francis Galaway, Laura Wood, Gavin J Wright, View ORCID ProfileAlexander D Douglas Publicado en: TBD, Issue TBD, 2020, Page(s) TBD Editor: TBD DOI: 10.1101/2020.02.02.929190 Derechos de propiedad intelectual Patent (2) MULTIVALENT MALARIA TRANSMISSION-BLOCKING VACCINES Número de solicitud/publicación: 20 20058906 Fecha: 2020-03-30 Solicitante(s): STATENS SERUM INSTITUT VACCINE IMMUNOGENS Número de solicitud/publicación: 20 728129 Fecha: 2020-05-11 Solicitante(s): THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Buscando datos de OpenAIRE... Se ha producido un error en la búsqueda de datos de OpenAIRE No hay resultados disponibles